The table below shows Nurix Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$71.91M
-$61.09M
-$41.95M
-$48.45M
-$42.63M
$8.05M
Capital expenditure
$1.04M
$3.48M
$2.88M
$2.28M
$3.47M
$843.00K
Investing cash flow
-$123.83M
$25.53M
$35.51M
$16.07M
$40.03M
-$2.39M
Dividends paid
-
-
-
-
NRIX operating cash flow (10-K history)
Nurix Therapeutics, Inc. reported operating cash flow of -$249.47M for fiscal year 2025. That is down 44.5% from -$172.58M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $601.00K (FY 2019) to -$249.47M. Figures come from the company's audited annual reports as filed with the SEC.